Objective:

To evaluate the safety and efficacy of pimavanserin specifically for dementia-related psychosis in patients with Lewy body dementia (PDD and DLB) from the HARMONY trial.

Key Findings:

• Pimavanserin demonstrated efficacy in reducing psychosis relapse in patients with Lewy body dementia, with a statistically significant reduction in relapse rates.
• Patients who continued pimavanserin had a lower risk of relapse compared to those who received placebo, with a relative risk reduction of X% (insert specific data).
• The treatment was well-tolerated with a favorable safety profile, with adverse events reported in Y% of patients (insert specific data).

Interpretation:

Pimavanserin is a promising treatment option for managing dementia-related psychosis in patients with Lewy body dementia, showing significant efficacy and safety.

Limitations:

• The study was a post hoc analysis, which may introduce bias due to the non-randomized nature of subgroup selection.
• The sample size for PDD and DLB was relatively small compared to the overall population, limiting the generalizability of the findings.

Conclusion:

Pimavanserin is effective and safe for treating psychosis in Lewy body dementia patients, warranting further research in larger cohorts to validate these findings.